@prefix : <http://www.transceleratebiopharmainc.com/EP_1/V1#> .
@prefix pr: <http://www.assero.co.uk/Protocol#> .
@prefix isoC: <http://www.assero.co.uk/ISO11179Concepts#> .
@prefix isoT: <http://www.assero.co.uk/ISO11179Types#> .
@prefix isoR: <http://www.assero.co.uk/ISO11179Registration#> .
@prefix isoI: <http://www.assero.co.uk/ISO11179Identification#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .

<http://www.transceleratebiopharmainc.com/EP_1/V1>
	rdf:type owl:Ontology ;
.
:END
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 1"^^xsd:string ;
	isoT:hasState :END_RS ;
	isoT:hasIdentifier :END_SI ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to [[[Timepoint]]] in the Alzheimer’s Disease Assessment Scale – Cognitive Assessment (ADAS-Cog) 14 total score"^^xsd:string ;
.
:END_RS
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
:END_SI
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 1"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_2/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 2"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_2/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_2/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week [[[Timepoint]]] in the Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+)"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_2/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_2/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 2"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_3/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 3"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_3/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_3/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change [absolute] in HbA1c from baseline to [[[Timepoint]]]"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_3/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_3/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 3"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_4/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 4"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_4/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_4/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to [[[Timepoint]]] in the [[[BC]]]"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_4/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_4/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 4"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_5/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 5"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_5/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_5/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with adverse events, serious adverse events (SAEs), and adverse events leading to study intervention discontinuation over the [x-week] study intervention period"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_5/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_5/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 5"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_6/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 6"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_6/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_6/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to [[[Timepoint]]] in continuous laboratory tests: Hepatic Function Panel"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_6/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_6/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 6"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_7/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 7"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_7/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_7/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with abnormal (high or low) laboratory measures (urinalysis) during the postrandomization phase"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_7/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_7/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 7"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_8/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 8"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_8/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_8/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to [[[Timepoint]]] in ECG parameter: QTcF"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_8/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_8/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 8"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/EP_9/V1#END>
	rdf:type pr:Endpoint ;
	isoC:label "Endpoint 9"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/EP_9/V1#END_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/EP_9/V1#END_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T13:46:33+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to [[[Timepoint]]] in the [[[Assessment]]]"^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/EP_9/V1#END_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/EP_9/V1#END_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "EP 9"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.